IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic…

Overview of attention for article published in Journal of Clinical Oncology, May 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 6 news outlets

patent: 1 patent

Readers on

mendeley: 11 Mendeley

So far, Altmetric has seen 9 news stories from 6 outlets.

FDA News Recap: Novel Drug Approvals in First Half of 2024

HCP Live, 01 Jul 2024

Credit: US Food and Drug Administration The first half of 2024 has been nothing short of historic for the medical community.

Oncology Drugs Approved by the FDA in June 2024

Oncology Nursing News, 01 Jul 2024

Throughout the month of June, several cancer therapies have received FDA approval for diseases including thyroid cancer…

Imetelstat Gets FDA Approval for Low- to Intermediate-1-Risk MDS With Transfusion-Dependent Anemia

Oncology Nursing News, 07 Jun 2024

The FDA granted an approval to imetelstat for certain patients with low- to intermediate-1-risk MDS who have transfusion-dependen…

EMA Validates MAA for Imetelstat for Transfusion-Dependent Anemia in Lower-Risk MDS

OncLive, 03 Oct 2023

John A. Scarlett, MD The European Medicines Agency (EMA) has validated the marketing authorization application for the use of…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 5 additional news stories.